Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Polygonatum sibiricum polysaccharide ameliorates intestinal barrier dysfunction in aging mice via gut microbiota-metabolite modulation and TLR4/NF-κB pathway inhibition.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guan Peiyao, Zeng Xin, Li Ziye, Wang Qian, Ding Han, Wang Tingting, Wang Jiayun, Fu Yansong, Chen Lizhang, Qin Hong
Аннотация
BACKGROUND: Intestinal barrier dysfunction is a critical pathological feature of aging-related diseases. Polygonatum sibiricum polysaccharide (PSP), a natural bioactive compound, has been reported to possess microbiota-regulatory and immunomodulatory properties; however, its protective effects against aging-induced intestinal barrier injury and the underlying mechanisms remain unclear.
PURPOSE: This study aimed to investigate the protective effects of PSP on age-related intestinal barrier dysfunction and to elucidate the underlying mechanisms, with a particular focus on the microbiota-metabolism-immunity axis.
STUDY DESIGN: A combination of in vivo and in vitro experiments, together with multi-omics analyses and network pharmacology, was employed to systematically evaluate the effects and mechanisms of PSP in aging-associated intestinal barrier injury.
METHODS: Ultraviolet (UV) spectroscopy, gel permeation chromatography (GPC), high-performance liquid chromatography-mass spectrometry (HPLC-MS), and Fourier-transform infrared spectroscopy (FT-IR) were adopted to comprehensively characterize the purity and detailed structural profiles of PSP. Naturally aged mice were orally administered PSP (400 mg/kg) to assess intestinal barrier integrity, permeability, inflammatory responses, and gut microbiota composition. In vitro, D-galactose (D-gal)-induced senescent Caco-2 cells were treated with PSP (100, 200, and 400 μg/ml) to evaluate cellular senescence, tight junction protein expression, and pro-inflammatory cytokine production. Network pharmacology analysis was conducted to predict key signaling pathways involved, followed by experimental validation and reverse confirmation using a TLR4 agonist.
RESULTS: Characterization by UV spectroscopy and GPC confirmed the purity and molecular weight distribution of PSP, respectively; monosaccharide analysis revealed it was mainly composed of glucose, mannose, and galactose, and FT-IR identified its characteristic functional groups. In naturally aged mice, PSP administration significantly improved intestinal barrier integrity, reduced intestinal permeability, alleviated inflammatory responses, and reshaped gut microbiota composition. In Caco-2 cells, PSP dose-dependently attenuated D-gal-induced cellular senescence, restored tight junction protein expression, and suppressed pro-inflammatory cytokine production. Network pharmacology analysis identified the TLR4/NF-κB signaling pathway as a potential key target of PSP, which was further confirmed by both in vivo and in vitro experiments.
CONCLUSIONS: Collectively, these findings demonstrate that PSP alleviates aging-associated intestinal barrier dysfunction through multi-level regulation involving the microbiota-metabolism-immunity axis and supports its potential as a natural therapeutic candidate for anti-aging interventions.
PURPOSE: This study aimed to investigate the protective effects of PSP on age-related intestinal barrier dysfunction and to elucidate the underlying mechanisms, with a particular focus on the microbiota-metabolism-immunity axis.
STUDY DESIGN: A combination of in vivo and in vitro experiments, together with multi-omics analyses and network pharmacology, was employed to systematically evaluate the effects and mechanisms of PSP in aging-associated intestinal barrier injury.
METHODS: Ultraviolet (UV) spectroscopy, gel permeation chromatography (GPC), high-performance liquid chromatography-mass spectrometry (HPLC-MS), and Fourier-transform infrared spectroscopy (FT-IR) were adopted to comprehensively characterize the purity and detailed structural profiles of PSP. Naturally aged mice were orally administered PSP (400 mg/kg) to assess intestinal barrier integrity, permeability, inflammatory responses, and gut microbiota composition. In vitro, D-galactose (D-gal)-induced senescent Caco-2 cells were treated with PSP (100, 200, and 400 μg/ml) to evaluate cellular senescence, tight junction protein expression, and pro-inflammatory cytokine production. Network pharmacology analysis was conducted to predict key signaling pathways involved, followed by experimental validation and reverse confirmation using a TLR4 agonist.
RESULTS: Characterization by UV spectroscopy and GPC confirmed the purity and molecular weight distribution of PSP, respectively; monosaccharide analysis revealed it was mainly composed of glucose, mannose, and galactose, and FT-IR identified its characteristic functional groups. In naturally aged mice, PSP administration significantly improved intestinal barrier integrity, reduced intestinal permeability, alleviated inflammatory responses, and reshaped gut microbiota composition. In Caco-2 cells, PSP dose-dependently attenuated D-gal-induced cellular senescence, restored tight junction protein expression, and suppressed pro-inflammatory cytokine production. Network pharmacology analysis identified the TLR4/NF-κB signaling pathway as a potential key target of PSP, which was further confirmed by both in vivo and in vitro experiments.
CONCLUSIONS: Collectively, these findings demonstrate that PSP alleviates aging-associated intestinal barrier dysfunction through multi-level regulation involving the microbiota-metabolism-immunity axis and supports its potential as a natural therapeutic candidate for anti-aging interventions.